OBSN Stock Overview
A biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ObsEva SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 0.0012 |
| 52 Week High | CHF 0.085 |
| 52 Week Low | CHF 0.0012 |
| Beta | 0.64 |
| 11 Month Change | 0% |
| 3 Month Change | -92.50% |
| 1 Year Change | -98.15% |
| 33 Year Change | -99.96% |
| 5 Year Change | -99.99% |
| Change since IPO | -99.99% |
Recent News & Updates
ObsEva SA (VTX:OBSN) Surges 84% Yet Its Low P/S Is No Reason For Excitement
Feb 09
Benign Growth For ObsEva SA (VTX:OBSN) Underpins Its Share Price
Dec 26Shareholder Returns
| OBSN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | -11.1% | -1.4% |
| 1Y | -98.2% | 103.0% | 4.8% |
Return vs Industry: OBSN underperformed the Swiss Biotechs industry which returned 57.4% over the past year.
Return vs Market: OBSN underperformed the Swiss Market which returned 3.6% over the past year.
Price Volatility
| OBSN volatility | |
|---|---|
| OBSN Average Weekly Movement | 42.5% |
| Biotechs Industry Average Movement | 12.4% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.5% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: OBSN's share price has been volatile over the past 3 months.
Volatility Over Time: OBSN's weekly volatility has increased from 31% to 42% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 15 | Fabien de Ladonchamps | www.obseva.com |
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA Fundamentals Summary
| OBSN fundamental statistics | |
|---|---|
| Market cap | CHF 140.61k |
| Earnings (TTM) | CHF 7.12m |
| Revenue (TTM) | CHF 17.65m |
0.0x
P/E Ratio0.0x
P/S RatioIs OBSN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBSN income statement (TTM) | |
|---|---|
| Revenue | US$19.64m |
| Cost of Revenue | US$10.71m |
| Gross Profit | US$8.93m |
| Other Expenses | US$1.01m |
| Earnings | US$7.92m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Sep 30, 2024
| Earnings per share (EPS) | 0.068 |
| Gross Margin | 45.46% |
| Net Profit Margin | 40.34% |
| Debt/Equity Ratio | 0% |
How did OBSN perform over the long term?
See historical performance and comparison